HeartBeam to Attend Key Investor Conferences in March 2026

Written by Emily J. Thompson, Senior Investment Analyst

Source: Yahoo Finance

Updated: 1 day ago

0mins

BEAT-8.78%

Should l Buy BEAT?

Source: Yahoo Finance

Investor Conference Schedule: HeartBeam's CEO Robert Eno and CFO Timothy Cruickshank will attend the Oppenheimer 36th Annual Healthcare MedTech & Services Conference on March 16-17, 2026, where they will host a webcast presentation and one-on-one meetings with investors to enhance the company's visibility among stakeholders.
Industry Engagement Opportunity: At the ROTH Conference on March 23-24, 2026, CEO Eno will participate in a panel discussion on ‘Technologies Advancing Healthy Aging,’ showcasing HeartBeam's innovations in cardiac health management and further solidifying its leadership position in the industry.
Scientific Conference Participation: The HeartBeam team will attend the American College of Cardiology's annual conference (ACC.26) from March 28-30, 2026, showcasing their FDA-cleared HeartBeam System at booth #209 and demonstrating the working prototype of the 12-lead ECG extended wear patch to physicians and potential partners, thereby enhancing market awareness.
Technology Innovation Showcase: HeartBeam's 3D ECG technology received FDA clearance in 2024, aimed at providing real-time cardiac health monitoring through portable devices, which is expected to redefine the future of cardiac health management and improve patient health management experiences.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy BEAT?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on BEAT

Wall Street analysts forecast BEAT stock price to rise

3 Analyst Rating

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 1.480

Low

4.00

Averages

5.83

High

8.00

Current: 1.480

Low

4.00

Averages

5.83

High

8.00

Roth Capital

NULL -> Buy

initiated

2025-10-31

Reason

Roth Capital

Price Target

AI Analysis

2025-10-31

initiated

NULL -> Buy

Reason

Roth Capital initiated coverage of HeartBeam with a Buy rating and $4 price target. The company is developing a credit-card-sized, cable-free cardiac device that synthesizes a 12-lead electrocardiogram, the analyst tells investors in a research note. The firm expects FDA clearance in the "coming days" that will initially focus on advanced cardiac arrhythmias within the concierge medicine market.

About BEAT

HeartBeam, Inc. is a cardiac technology company. The Company focuses on developing and commercializing higher resolution ambulatory Electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease both inside and outside a healthcare facility setting. It is engaged in the development of higher resolution ECG solutions is achieved through the development of the Company’s proprietary and patented electrocardiography technology platform. It is developing three-dimensional (3D) representations of cardiac electrical activity by displaying the spatial locations of ECG waveforms. It is developing its own product, the HeartBeam System. The HeartBeam System comprises a credit card sized 12-lead output electrocardiogram device, a patient application, a physician portal, and powerful cloud-based algorithms. The core technology consists of a series of patented inventions that allow it to capture the heart’s electrical activity from three distinct directions.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

HeartBeam Partners with Mount Sinai for AI Heart Monitoring

11 hours agoNASDAQ.COM

Strategic Collaboration: HeartBeam has announced a strategic partnership with the Icahn School of Medicine at Mount Sinai to accelerate the development of AI-enabled heart monitoring technology, which is expected to drive innovation in cardiac health management.
Integration of Technical Expertise: This partnership combines Mount Sinai's clinical and AI expertise with HeartBeam's patented 3D electrocardiogram platform, enabling the collection of 12-lead ECG data anytime and anywhere, thus expanding the applications of heart monitoring.
AI Algorithm Development: By pairing high-fidelity ECG data with clinically annotated datasets, the collaboration aims to create advanced AI algorithms capable of assessing heart health trends earlier, detecting risks, and guiding more precise care.
Market Potential Enhancement: This collaboration positions HeartBeam to move beyond rhythm monitoring into AI-enabled disease assessment and management, potentially unlocking new opportunities in preventive cardiology, chronic disease management, and remote patient monitoring.

HeartBeam Partners with Mount Sinai for AI-ECG Development

11 hours agoBenzinga

AI-ECG Collaboration: HeartBeam's partnership with Mount Sinai aims to combine its patented ECG platform with the hospital's AI and clinical expertise to develop and validate advanced AI-ECG algorithms, enhancing the accuracy and efficiency of cardiac health monitoring.
Data Integration Advantage: The collaboration will leverage HeartBeam's real-world ECG datasets alongside Mount Sinai's clinically annotated data to train and validate new AI models, expected to drive the development of personalized algorithms that enable 12-lead ECG assessments outside traditional clinical settings.
Accelerated Algorithm Development: HeartBeam's in-house AI team will collaborate with Mount Sinai researchers to develop, train, and validate a suite of AI-ECG algorithms intended to provide patient wellness insights, condition-focused assessments, and chronic condition management, expanding the application scenarios of the cardiac monitoring platform.
Stock Price Surge: HeartBeam shares rose 6.08% to $1.57 at the time of publication, reflecting positive market sentiment towards the collaboration's prospects, which may enhance investor confidence in the company's future growth potential.

HeartBeam Partners with Mount Sinai to Develop AI-ECG Algorithms

13 hours agoseekingalpha

Strategic Collaboration: HeartBeam has entered a strategic partnership with the Icahn School of Medicine at Mount Sinai to develop and validate next-generation AI-ECG algorithms, leveraging HeartBeam's patented 3D ECG platform to enhance AI-enabled cardiac monitoring as part of the company's broader ecosystem strategy.
Research Team Formation: Led by Lance Myers, HeartBeam's AI team will collaborate with Mount Sinai researchers to develop and validate advanced AI-ECG algorithms, with guidance from Joshua Lampert, Vivek Reddy, and Girish Nadkarni, ensuring the effectiveness and practicality of the technology.
Positive Market Reaction: Following the announcement, HeartBeam's shares rose by 5.71%, indicating market recognition of the company's innovative capabilities in cardiac monitoring, which may attract more investor interest in its future growth potential.
Ecosystem Strategy Enhancement: This collaboration with Mount Sinai not only strengthens HeartBeam's technological capabilities but also solidifies its competitive position in the cardiac health monitoring market, signaling long-term growth potential in the medical technology sector.